Pular para o conteúdo principal
Ranking Invest

ORGO - Organogenesis Holdings Inc.

Segmento: HealthcareOrganogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.

Análise Ranking Invest

Valuation estimado
-9,15%
$ 59.20 Mi
Valor de Mercado
$ 190.44 Mi
Sobrepreço (AV)+221.7%
IVR
0.31A companhia vale 0,31 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-0.49O valuation alternativo equivale a -49% do valor de mercado da companhia.
MLL
-0.49O lucro líquido dos controladores em 16 trimestres equivale a -49% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 148.27 Mi

Dívida Líquida

-$ 46.10 Mi

L4T

-$ 84.16 Mi

MM4T

-82.28%

Indicadores Básicos

ROE

-56.76%

Índices de Previsibilidade

Receita Líquida

E0.23

Lucro

E1.58

Margem

E1.30

Índices de Tendência

Receita Líquida

D-1.20

Lucro

F-4.68

Margem

F-5.12

Índices de Endividamento

DIV/PAT

-0.31

DIV/L4T

0.55

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.